How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

634 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. (Abstract)

Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. Refractory cutaneous warts are difficult to eliminate. In situ photo-immunotherapy (ISPI) is an innovative treatment concept combining local photothermal therapy (PTT) and topical immunotherapy using imiquimod. To compare the efficacy of ISPI vs topical imiquimod alone, a prospective randomized controlled trial was performed with patients suffering from refractory (...) cutaneous warts. In both groups, approximately 50% of the skin surface containing warts was treated for 6 weeks. On the basis of topical imiquimod, ISPI includes an additional 808 nm laser irradiation. Treatment response, temperatures during irradiation and histopathologic examination were evaluated. The complete response rate in the ISPI-group (22/36, 61.1%) was significantly higher than in the imiquimod alone group (11/34, 32.4%). In the ISPI-group, the mean maximum temperature was 44.5 ± 5.1°C

2019 Journal of biophotonics Controlled trial quality: uncertain

2. Wart Immune Therapy

) These images are a random sampling from a Bing search on the term "Wart Immune Therapy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content (...) Wart Immune Therapy Wart Immune Therapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Wart Immune Therapy Wart Immune Therapy Aka

2018 FP Notebook

3. Cimetidine wart therapy

wart therapy Aka: Cimetidine wart therapy From Related Chapters II. Indication Recalcitrant warts in adults in Children III. Mechanism Mild Immune enhancing effect IV. Dosing Start: 25-40 mg/kg (MAX 400 mg tid) divided bid-tid Course: Treat for 2-3 months V. Side effects Unpleasant syrup s with prolonged use VI. Efficacy: Mild effect Not nearly as pronounced as originally thought VII. References Images: Related links to external sites (from Bing) These images are a random sampling from a Bing (...) search on the term "Cimetidine wart therapy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content is with systematic literature reviews

2018 FP Notebook

4. Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. (Abstract)

Clearance of recalcitrant warts in a patient with idiopathic immune deficiency following administration of the quadrivalent human papillomavirus vaccine. Human papillomavirus (HPV)-induced cutaneous warts are potentially serious and debilitating. In immunosuppressed patients, these warts may be resistant to standard therapies. We report a case of a young patient with a primary immune deficiency whose recalcitrant cutaneous warts regressed completely following administration of a quadrivalent

2017 Clinical & Experimental Dermatology

5. British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy

hyperplasia, viral warts, vulval lichen sclerosus, vulvodynia, wound healing and Zoon balanitis. © 2018 British Association of Dermatologists British Journal of Dermatology (2018) 4 BAD and BPG guidelines for topical photodynamic therapy 2018, T.H. Wong et al.? where the Paget cell in?ltrate is less dense ? when there is limited adnexal involvement. R20 ( ) Consider PDT as a treatment option for EMPD either before or after surgery. R21 ( ) Consider CO 2 laser prior to PDT as a treatment option for EMPD (...) Protocols for delivery of photodynamic therapy A successful PDT outcome requires the optimization of apply- ing the appropriate prodrug, drug or photosensitizer, light parameters and oxygen, thereby achieving the mechanism of action intended. The resultant photodynamic reaction at the target cell produces the therapeutic result. PDT utilizes the higher selectivity of the photosensitizer for the target tissue compared with healthy tissue. The topically applied photosen- sitizer prodrugs are converted

2019 British Association of Dermatologists

6. Topical Photodynamic therapy

Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence. Keywords: 5-aminolaevulinic acid, dermatology, guidelines, methyl aminolaevulinate, non- melanoma skin cancer, topical photodynamic therapy. 1. Introduction Photodynamic therapy (PDT) involves the activation of a photosensitizing drug by visible light to produce reactive oxygen species within target cells, resulting in their destruction with additional immune-modulatory effects (...) Pharmaceuticals, USA), is approved in N. America and certain other countries for AK, in a protocol that uses blue light. Many original studies of topical PDT used non-standardized preparations of ALA made in hospital pharmacies, so direct comparison of early studies may not be valid. Topical PDT is approved for the treatment of certain non-melanoma skin cancers (NMSC) in the immune-competent, used both as lesional or area/field-therapy, and has the potential to delay/reduce the development of new AK, although

2019 European Dermatology Forum

7. Safety and Efficacy of Immune Therapy for Condyloma

of Shenzhen Second People's Hospital - Exclusion Criteria:pregnant, blood disease, contraindication for immune therapy, allergic to interferon Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03158480 Locations Layout table for location information China (...) Safety and Efficacy of Immune Therapy for Condyloma Safety and Efficacy of Immune Therapy for Condyloma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy of Immune Therapy for Condyloma

2017 Clinical Trials

8. Sex or Drugs: Why Do We See An Increased Incidence of Oropharyngeal Cancer?

, but also to inform safe sex counseling and screening for cancer risk factors for all patients. Dr. Tyler Litton a former NYU medical student is a current radiology resident at Saint Louis University School of Medicine Peer reviewed by Howard Leaf, MD, Medicine, NYU Langone Medical Center Image courtesy of Wikimedia Commons References Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol . 2011;29(32):4294-4301 (...) Sex or Drugs: Why Do We See An Increased Incidence of Oropharyngeal Cancer? Sex or Drugs: Why Do We See An Increased Incidence of Oropharyngeal Cancer? – Clinical Correlations Search Sex or Drugs: Why Do We See An Increased Incidence of Oropharyngeal Cancer? July 13, 2016 5 min read By Tyler Litton, MD Peer Reviewed Oropharyngeal squamous cell carcinoma (OPSCC) is . [1] Tonsillar cancer is the most common type of OPSCC followed by base of tongue cancer, .[2] The incidence of both tonsillar

2016 Clinical Correlations

9. UK National Guidelines on the Management of Anogenital Warts

: Ullstein Mosby, 1997:54-6. 35 Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984;63:703-7. 23 36 Nathan M. Outpatient treatment of intrameatal warts in a genitourinary medicine department. Int J STD AIDS 1994;5:218-20. 37 Nathan M, Hickey N, Mayuranathan L et al. Treatment of anal human papillomavirus disease – a long term outcome study. Int J STD AIDS 2008;19:445-9. 38 Woodhall SC, Jit M, Soldan K et al. The impact of genital warts: loss of quality of life and cost (...) with or without coincidental benign warts. This includes intraepithelial neoplasia affecting the vulva (VIN), vagina (VaIN), perianal area (PAIN), anus (AIN) and penis (PIN). The diagnosis of intraepithelial neoplasia is made through histology. The presence of pigmentation, depigmentation, pruritus, underlying immune-deficiency, prior history of intraepithelial neoplasia on the same or distant anogenital sites, may raise suspicion of anogenital neoplasia. 6 Assessment of the patient with anogenital warts

2015 British Association for Sexual Health and HIV

10. Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. (Abstract)

Intralesional Injection of the Measles-Mumps-Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial. Common resistant-to-therapy warts pose a challenge to both clinicians and patients. Among many destructive and immunotherapeutic options, no single, fully effective treatment has been suggested yet. Many investigations, including those using intralesional antigen administrations, have demonstrated that cellular immunity plays a major role in the clearance of human (...) papilloma virus (HPV) infection. The aim of the present study was to evaluate the effects of the intralesional injection of the measles-mumps-rubella (MMR) vaccine into resistant-to- treatment palmoplantar warts and its complications.In this single-blind, randomized, controlled clinical trial, 60 cases with resistant-to-therapy palmoplantar warts referring to the Dermatology Clinic of Bou-Ali Sina Hospital of Sari between June 2015 and 2016 were randomly assigned to 2 equal groups: the MMR Group

2019 Iranian journal of medical sciences Controlled trial quality: uncertain

11. Expression of PD-L1 and PD-1 in Cutaneous Warts. (Abstract)

/8, 63%).This was a retrospective observational study conducted at a single institution.Many cutaneous warts express PD-L1, suggesting that human papillomavirus might use this pathway to promote immune dysfunction. This discovery helps explain the recalcitrance of warts to current therapies and provides a rationale for investigating anti-PD-1 immunotherapy as a potential treatment for warts.Copyright © 2019 American Academy of Dermatology, Inc. All rights reserved. (...) Expression of PD-L1 and PD-1 in Cutaneous Warts. Cutaneous warts have high prevalence and cause significant morbidity. Understanding the mechanisms by which warts evade the immune system could lead to targeted and improved treatments.To determine whether cutaneous warts express programmed cell death ligand 1 (PD-L1) and to characterize the expression of programmed cell death 1 (PD-1) within the immune infiltrate of inflamed lesions.In total, 44 biopsies of cutaneous warts were retrieved from

2019 Journal of American Academy of Dermatology

12. Wart Immune Therapy

) These images are a random sampling from a Bing search on the term "Wart Immune Therapy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Pharmacology About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians. Started in 1995, this collection now contains 6656 interlinked topic pages divided into a tree of 31 specialty books and 728 chapters. Content (...) Wart Immune Therapy Wart Immune Therapy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Wart Immune Therapy Wart Immune Therapy Aka

2015 FP Notebook

13. Warts - anogenital

treatments . Site of lesions — podophyllotoxin cream may be easier to apply than the solution, especially for less accessible lesions. Other considerations include the availability, cost of treatment, the person's preference and any other co-existing medical conditions. Table 1. Clearance and recurrence rates of genital wart treatments Drug Clearance rate range* Recurrence rate range Imiquimod cream 5% 35–68% 6–26% Podophyllotoxin solution 0.5% 45–83% 13–100% Podophyllotoxin cream 0.15% 43–70% 6–55 (...) process for external stakeholders. Competing interests declared for this topic: None. References References ABPI ( 2015 ) SPC for Catephen 10% Ointment. Electronic Medicines Compendium. Datapharm Communications Ltd. . [ ] BASHH ( 2015 ) UK national guidelines on the management of anogenital warts. British Association for Sexual Health and HIV. . [ ] BMJ ( 2016 ) Genital warts. BMJ Best Practice. . BNF 73 (2017) British National Formulary. 73rd edn. London: British Medical Association and Royal

2017 NICE Clinical Knowledge Summaries

14. Infrared Bioeffect System for the Treatment of Cutaneous Warts

followed by clearance of other distant lesions, a phenomenon suggesting that local hyperthermia could aid in establishing a specific immune response to eliminate HPV.So the purpose of the study is to evaluate the safety and efficacy of controllable infrared bioeffect system to treat cutaneous warts. This trial was designed into two groups, one was experimental group (thermal therapy group), the other one was control group (liquid nitrogen cryotherapy group). The ratio of participants was 1:1 (...) Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Gao Xinghua, First Hospital of China Medical University: hyperthermia human papilloma virus cutaneous warts Additional relevant MeSH terms: Layout table for MeSH terms Papilloma Warts Neoplasms, Squamous Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type

2018 Clinical Trials

15. Sinecatechins ointment 10% (Veregen<sup>®</sup> ) for genital warts: percutaneous penetration of Epigallocatechin Gallate concentrations in the stratum corneum collected by adhesive tape stripping method. Full Text available with Trip Pro

collected by adhesive tape stripping method. e357-e358 10.1111/jdv.14933 de Vries H J C HJC Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. STI Outpatient Clinic, Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands. Soltanipoor M M Coronel Laboratory for Occupational (...) & Environmental Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Kezic S S Coronel Laboratory for Occupational & Environmental Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. Vergunst C E CE Amsterdam Infection and Immunity Institute (AI&II), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. eng Letter 2018 03 30 England J Eur Acad Dermatol Venereol 9216037 0926-9959 2018 3 11 6 0 2018 3 11 6 0 2018 3 11 6 0

2018 Journal of the European Academy of Dermatology and Venereology

16. The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts

that has been damaged slightly . A number of types exist including: common warts, plantar warts, filiform warts, and genital warts . Genital warts are often sexually transmitted. Condition or disease Intervention/treatment Phase Warts Drug: Bleomycin Drug: Purified Protein Derivative Phase 4 Detailed Description: Selection of the most appropriate means of treatment is usually difficult because of the availability of various therapeutic lines and also due to the variability in the immune status (...) of the patients for treatment of warts. There are on two main therapeutic options: the first is the conventional destructive and aggressive method, which includes treatment with chemical cautery, cryo- therapy, electro cauterization, surgical excision, and laser ablation . This method depends on destruction of the area of epidermis infected with the virus. The recurrence rates after these therapy modalities maybe high. The second is the immunotherapy, which is based on the activation of the immune system

2018 Clinical Trials

17. An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone Full Text available with Trip Pro

101665210 2352-5126 CA, candida antigen immune therapy papillomavirus 2018 4 25 6 0 2018 4 25 6 0 2018 4 25 6 1 epublish 29687060 10.1016/j.jdcr.2018.01.010 S2352-5126(18)30019-5 PMC5909483 Br J Dermatol. 2011 Aug;165(2):233-46 21219294 J Drugs Dermatol. 2004 May-Jun;3(3):263-5 15176159 Cutis. 2002 Sep;70(3):185-92 12353895 Dermatitis. 2005 Dec;16(4):216; author reply 216-7 16536337 Dermatitis. 2005 Mar;16(1):38-40 15996350 J Pediatr Adolesc Gynecol. 2003 Oct;16(5):269-83 14597015 Clin Dermatol. 1997 (...) An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone 29687060 2019 02 26 2352-5126 4 3 2018 Apr JAAD case reports JAAD Case Rep An aberrant reaction to Candida albicans antigen used for recalcitrant warts successfully treated with oral prednisone. 242-244 10.1016/j.jdcr.2018.01.010 La'Pelusa Andrew A Department of Dermatology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio. Rorex Jennifer J Department

2018 JAAD Case Reports

18. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. Full Text available with Trip Pro

and treatment in Swaziland. All identifiable direct medical costs were considered for cervical lesions, cervical cancer and genital warts, which were primary diagnoses during 2015. A mix of bottom up micro-costing ingredients approach and top-down approaches was used to collect data on costs. All costs were computed at the price level of 2015 and converted to dollars ($).The total annual estimated direct medical cost associated with screening, managing and treating cervical lesions, CC and genital warts (...) Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. Human papillomavirus (HPV) has proven to be the cause of several severe clinical conditions on the cervix, vulva, vagina, anus, oropharynx and penis. Several studies have assessed the costs of cervical lesions, cervical cancer (CC), and genital warts. However, few have been done in Africa and none in Swaziland. Cost analysis is critical in providing useful information for economic evaluations

2017 PLoS ONE

19. Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.

. The secondary objective is to determine the tolerability of this new mode of administration of cidofovir in the pediatric population Condition or disease Intervention/treatment Phase Warts Drug: Cidofovir Phase 2 Detailed Description: This study includes pediatric patients with history of either primary or iatrogenic immune-suppression who are seeking treatment of warts that have already proven recalcitrant to standard therapy. The first cohort will include 4 patients ages 12 to 17. After all tests indicate (...) Date : June 2016 Actual Study Completion Date : June 2016 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Cidofovir Cidofovir clinical resolution of treated warts as evaluated by the investigators Drug: Cidofovir Cidofovir Outcome Measures Go to Primary Outcome Measures : Clinical resolution of treated warts as evaluated by the investigators [ Time Frame: 6 months ] Total or near-total

2015 Clinical Trials

20. Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. (Abstract)

Evaluation of specific humoral and cellular immune responses against the major capsid L1 protein of cutaneous wart-associated alpha-Papillomaviruses in solid organ transplant recipients. Infection with different species of cutaneous human papillomaviruses (cHPV) of genus alpha (cαHPVs) and associated skin disease are highly prevalent in solid organ transplant recipients (OTR), documenting the importance of the immunological control of HPV infection.To investigate the natural course of cαHPV (...) in humoral L1-specific immune responses during the course of iatrogenic immunosuppression, comparing median values 30 d before and 30 d after initiation of immunosuppressive therapy (p < 0.05). This difference disappeared after long-term (>1 year) immunosuppression. The predominant cellular L1-specific immune response was of type T(H)1 (CD4(+)CD40L(+)IL-2(+)IFN-γ(+)). Consistent with the detected L1-specific antibody titers, L1-specific T(H)1 responses were unchanged in long-term immunosuppressed OTR

2015 Journal of dermatological science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>